FATE THERAPEUTICS INC
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $6.6M | $13.6M | $63.5M | $96.3M | $55.8M | $31.4M | $10.7M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $107.8M | $135.0M | $172.6M | $320.5M | $215.5M | $125.6M | $87.8M |
| SG&A Expense | — | $46.5M | $74.2M | $81.4M | $84.2M | $57.3M | $33.9M | $23.6M |
| Operating Income | — | $-147.7M | $-210.3M | $-190.5M | $-308.4M | $-217.0M | $-128.1M | $-100.7M |
| Operating Margin | — | -2,222.4% | -1,542.6% | -299.9% | -320.2% | -388.6% | -407.5% | -943.1% |
| Interest Expense | — | — | — | — | — | $0 | $0 | $1.8M |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $2.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-136.3M | $-186.3M | $-160.9M | $-281.7M | $-212.2M | $-173.4M | $-98.1M |
| Net Margin | — | -2,051.1% | -1,366.5% | -253.3% | -292.5% | -379.9% | -551.6% | -919.0% |
| EPS (Basic) | — | $-1.15 | $-1.64 | $-1.64 | $-2.91 | $-2.24 | $-2.10 | $-1.44 |
| EPS (Diluted) | — | $-1.15 | $-1.64 | $-1.64 | $-2.91 | $-2.24 | $-2.10 | $-1.44 |
| Shares Outstanding (Basic) | 116.3M | 118.8M | 113.7M | 98.4M | 96.8M | 94.7M | 82.4M | 75.7M |
| Shares Outstanding (Diluted) | 116.3M | 118.8M | 113.7M | 98.4M | 96.8M | 94.7M | 82.4M | 75.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |